DiaSorin SpA engages in developing, producing and marketing reagent kits for laboratory diagnostics. The company is headquartered in Saluggia, Vercelli and currently employs 3,280 full-time employees. The company went IPO on 2007-07-19. The firm specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The firm develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. The company operates through ELISA immunodiagnostic business portfolio.
Follow-Up Questions
DiaSorin SpA 'in CEO'su kimdir?
Mr. Carlo Rosa 1998 'den beri şirketle birlikte olan DiaSorin SpA 'in Chief Executive Officer 'ıdır.
DSRLF hissesinin fiyat performansı nasıl?
DSRLF 'in mevcut fiyatı $94.25 'dir, son işlem günde 0% decreased etti.
DiaSorin SpA için ana iş temaları veya sektörler nelerdir?
DiaSorin SpA Health Care endüstrisine ait ve sektör Health Care 'dir
DiaSorin SpA 'in piyasa değerlemesi nedir?
DiaSorin SpA 'in mevcut piyasa değerlemesi $5.2B 'dir
DiaSorin SpA al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 18 analist DiaSorin SpA için analist derecelendirmeleri gerçekleştirdi, bunlar 4 güçlü al, 7 al, 6 tut, 2 sat ve 4 güçlü sat içermektedir